Physician profile
Annie Chang
NPI 1699738336
$2,011.24
in general payments reported to CMS, 2019-2025
20 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $133 · 2021: $213 · 2022: $342 · 2023: $317 · 2024: $255 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $527.14 | 2019-2024 | Hydrus Microstent, Clareon |
| Allergan, INC. | $225.29 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $154.48 | 2022-2024 | Vyzulta, Miebo |
| Abbvie INC. | $150.52 | 2022-2025 | Lumigan, Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.63 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $99.49 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $98.57 | 2019-2021 | |
| Akorn, INC. | $91.17 | 2019-2020 | |
| Oyster Point Pharma, INC. | $87.70 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $83.19 | 2019-2024 | |
| Horizon Therapeutics Plc | $66.50 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $65.45 | 2019-2020 | |
| Dompe US, INC. | $49.56 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $37.33 | 2020-2021 | |
| Shire North American Group INC | $36.05 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.59 | 2024 | Tepezza |
| Akorn Operating Company LLC | $22.61 | 2021 | |
| Thea Pharma INC. | $21.45 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.